Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.48 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.48 |
| ▸ | HTR1B known ✓ | P28222 | 3/20 | 0.47 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.47 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTR1F | P30939 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6958797 | 0.83 | HTR1A (0.38) | HTR1ADRD2ALDH1A1LMNAKMT2A | |
| SCHEMBL9336316 | 0.81 | HTR1A (0.58) | HTR1ADRD2HTR1BHTR1DALDH1A1 | |
| SCHEMBL6958771 | 0.81 | HTR1A (0.50) | HTR1ADRD2HTR1BHTR1DALDH1A1 | |
| SCHEMBL6965193 | 0.79 | HTR1A (0.56) | HTR1ADRD2HTR1BHTR1DALDH1A1 | |
| Oxalic Acid SCHEMBL9334144 | 0.79 | HTR1A (0.56) | HTR1ADRD2HTR1BHTR1DALDH1A1 | |
| SCHEMBL7971643 | 0.78 | HTR1A (0.43) | HTR1ADRD2HTR1BHTR1DALDH1A1 | |
| SCHEMBL6960098 | 0.77 | ALDH1A1 (0.51) | HTR1ADRD2HTR1BHTR1DALDH1A1 | |
| Hydrochloric Acid SCHEMBL6953846 | 0.77 | HTR1A (0.49) | HTR1ADRD2HTR1BHTR1DALDH1A1 | |
| Sulfuric Acid SCHEMBL6962963 | 0.76 | HTR1A (0.50) | HTR1ADRD2HTR1BHTR1DALDH1A1 | |
| Oxalic Acid SCHEMBL9334138 | 0.76 | HTR1A (0.55) | HTR1ADRD2HTR1BHTR1DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| EP-0882726-B1 | Carbazol-carboxamides as 5-HT1F agonists | LILLY CO ELI (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6221884-B1 | Carboxamides useful as 5-HT1F agonists | ELI LILLY AND COMPANY | 2001-04-24 | — | — | US | disclosed |
| WO-1998055115-A1 | CARBOXAMIDES USEFUL AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-12-10 | — | — | WO | disclosed |
| EP-0882726-A1 | Carbazol-carboxamides as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1A 2/4885DRD2 691/4885HTR1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.